Loading organizations...
§ Private Profile · Paris, Ile-de-France, France
Clinical-stage biotherapeutics company pioneering immunotherapies for oncology and autoimmune diseases using single-cell profiling and AI.
HiFiBiO Therapeutics is a clinical-stage biotherapeutics company pioneering immunotherapies by leveraging single-cell profiling technologies and AI/ML analytics to discover antibody drugs, with laboratories in Cambridge, Massachusetts, Paris, France, and Shanghai, China. The company utilizes its proprietary Drug Intelligence Science (DIS®) platform to understand cellular pathology and identify therapeutic targets across oncology and autoimmune disorders. Since 2017, HiFiBiO has discovered 8 clinical candidates, advancing 3 active Phase 1 clinical programs, including emunkitug (TNFR2 agonist), nuvustotug (OX40 agonist), and HFB200603 (BTLA antagonist), all of which have completed Phase 1a. The company has filed and cleared 6 INDs and secured over $180 million in financing from world-class investors. HiFiBiO was recognized as one of Fierce Biotech's "Fierce 15" in August 2023 for its innovative approach. The organization was founded in 2017 by Liang Schweizer, PhD.
HiFiBiO has raised $179.5M across 3 funding rounds.
HiFiBiO has raised $179.5M in total across 3 funding rounds.
HiFiBiO has raised $179.5M across 3 funding rounds. Most recently, it raised $75.0M Series D in June 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 14, 2021 | $75M Series D | Ryan Jeong | B Capital Group, Grand Mount, Hong Kong Science And Technology Parks Corporation, IDG Capital, Maison Capital, Sequoia Capital, Sherpa, Trinity Innovation Fund | Announced |
| Aug 28, 2019 | $67M Series C | IDG Capital | Delian Capital, Hanne Capital, Hongshan Capital Group (Sequoia Capital China), Kite, Lyfe Capital, VI Ventures | Announced |
| May 16, 2018 | $37.5M Series B | Lynn Yang, James Zhao | Nest.Bio Ventures, Proxima Ventures, VI Ventures | Announced |
HiFiBiO has raised $179.5M in total across 3 funding rounds.
HiFiBiO's investors include Ryan Jeong, B Capital Group, Grand Mount, Hong Kong Science and Technology Parks Corporation, IDG Capital, Maison Capital, Sequoia Capital, Sherpa, Trinity Innovation Fund, Delian Capital, Hanne Capital, Hongshan Capital Group (Sequoia Capital China).